Jazz Pharmaceuticals has agreed to a $145 million settlement in an antitrust lawsuit that accused the company of colluding with Hikma Pharmaceuticals to delay the entry of generic versions of Jazz’s narcolepsy medication, Xyrem, into the market. The legal proceedings brought against Jazz alleged that the company engaged in anti-competitive practices to maintain its hold on the lucrative narcolepsy drug market. The settlement was disclosed by Jazz on Tuesday, signaling the resolution of the litigation that has been closely watched in the pharmaceutical and legal communities.
For a detailed account of the case and its implications, visit the original article on Law360.